Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

36.30
-0.5400-1.47%
Post-market: 36.360.0600+0.17%19:51 EDT
Volume:6.19M
Turnover:225.49M
Market Cap:26.22B
PE:-77.23
High:37.18
Open:37.03
Low:36.23
Close:36.84
52wk High:37.97
52wk Low:11.60
Shares:722.41M
Float Shares:581.00M
Volume Ratio:1.12
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.20
PE(LYR):-67.22

Loading ...

Roivant Sciences - Brepocitinib Nda Approval and Launch in Dermatomyositis Expected by End of September 2026

THOMSON REUTERS
·
Aug 06

Roivant Sciences price target raised to $35 from $31.50 at BofA

TIPRANKS
·
Jul 31

Earning Preview: Roivant Sciences Ltd. Q2 revenue is expected to decrease by 71.57%, and institutional views are cautious

Earnings Agent
·
Jul 31

Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares

Reuters
·
Jul 30

Roivant Sciences Announces Annual General Meeting of Shareholders

Reuters
·
Jul 29

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700

Reuters
·
Jul 25

Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call

Reuters
·
Jul 24

Roivant to Report Q1 Results, Host Conference Call and Webcast

Reuters
·
Jul 24

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

THOMSON REUTERS
·
Jul 24

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents

MT Newswires Live
·
Jul 16

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000

Reuters
·
Jul 03

Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76

Reuters
·
Jul 02

QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million

Reuters
·
Jul 01

Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?

Simply Wall St.
·
Jun 30

Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million

Reuters
·
Jun 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015

Reuters
·
Jun 27

Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million

Reuters
·
Jun 27

Immunovant director Atul Pande disposes of USD 51,030 common shares

Reuters
·
Jun 17